Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2025-11-13 00:00:00 ET · period of report 2025-11-11 · accession 0001439222-25-000118 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-13 | 2025-11-11 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $25.01 | +2,454 | 64.2K | +4% | +$61.4K |
| D | 2025-11-13 | 2025-11-11 | AGIO | Gheuens Sarah | Chief Medical Off | S - Sale+OE | $43.78 | -2,454 | 61.7K | -4% | -$107.4K |
| D | 2025-11-13 | 2025-11-11 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $0.00 | -2,454 | 26.1K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-11-11 | M | A | 2,454 | $25.01 | 64,181 | D | — | — | |
| 2 | Common | Common stock | 2025-11-11 | S | D | 2,454 | $43.78 | 61,727 | D | — | — | (F2) The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $43.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Stock options (right to buy) | 2025-11-11 | M | D | 2,454 | $0.00 | 26,130 | D | $25.01 · — to 2033-03-01 | 2,454 Common stock | (F3) This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. |